A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 1981-1993

  Bifulco, Katia ^a   Longanesi Cattani, Immacolata ^a   Liguori, Eleonora ^a   Arra, Claudio ^a   Rea, Domenica ^a   Masucci, Maria Teresa ^a   De Rosa, Mario ^b   Pavone, Vincenzo ^c   Stoppelli, Maria Patrizia ^d   Carriero, Maria Vincenza ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLUTAMYLARGINYLPHENYLALANINE; F ACTIN; FOCAL ADHESION KINASE; PROTEIN KINASE B; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ACTIN POLYMERIZATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CONTROL; CELL MIGRATION; CELL MOTILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; FEMALE; FOCAL ADHESION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RABBIT; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CORNEAL KERATOCYTES; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RABBITS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885640117     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0077     Document Type: Article

References (45)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407: 249-57.
2. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7: 834-46.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285: 1182-6.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438: 967-74.
5. Ebon JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8: 210-21.
6. Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006;63: 601-15.
7. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007;100: 782-94.
8. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001;13: 563-8.
9. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264: 569-71.
10. Alexander RA, Prager GW, Mihaly-Bison J, Uhrin P, Sunzenauer S, Binder BR, et al. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 2012;94: 125-35.
11. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991;266: 1926-33.
12. Smith HW, Marshall CJ. Regulation of cell signaling by uPAR. Nat Rev Mol Cell Biol 2010;11: 23-36.
13. Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002;3: 932-43.
14. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22: 205-22.
15. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25: 349-55.
16. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14: 5785-93.
17. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008;13: 6752-62.
18. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007;97: 336-42.
19. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21: 1104-17.
20. Bifulco K, Longanesi-Cattani I, Gala M, DI Carluccio G, Masucci MT, Pavone V, et al. The soluble form of urokinase receptor promotes angiogenesis through its Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence. J Thromb Haemost 2010;8: 2789-99.
21. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, et al. The fibrinolytic receptor for urokinase activates the G proteincoupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002;99: 1359-64.
22. Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, et al. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem 2005;280: 25225-32.
23. Bifulco K, Longanesi-Cattani I, Franco P, Pavone V, Mugione P, Di Carluccio G, et al. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion. PLoS One 2012;7:e44806.
24. Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, et al. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett 2008;582: 1141-6.
25. Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther 2009;8: 2708-17.
26. Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc 2010; 5: 628-35.
27. Masucci MT, Pedersen N, Blasi F. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem 1991;266: 8655-8.
28. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, et al. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 1994;54: 5445-54.
29. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88: 277-85.
30. Yang S, Graham J, Kahn JW, Schwartz EA, Gerritsen ME. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am J Pathol 1999;155: 887-95.
31. Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, et al. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One 2012;7:e46536.
32. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003;162: 1431-9.
33. Mohan RR, Tovey JCK, Sharma A, Schultz GS, Cowden JW, Tandon A. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One 2011;6:e26432.
34. Rousseau S, Houle F, Huot J. Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med 2000;10: 321-7.
35. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12: 5018-22.
36. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. Mechanisms of integrin-vascular endothelial growth factor receptor crossactivation in angiogenesis. Circ Res 2007;10: 570-80.
37. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of avb3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18: 882-92.
38. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001;49: 568-81.
39. Misra RM, Bajaj MS, Kale VP. Vasculogenic mimicry of HT1080 tumor cells in vivo: critical role of HIF-1a-neuropilin-1 axis. PLoS One 2012;7: e50153.
40. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009;14: 4575-87.
41. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: ameta-analysis of randomized controlled trials. Acta Oncol 2010;49: 287-97.
42. Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009;6: 315-26.
43. Del Rosso M, Margheri F, Serratì S, Chillà A, Laurenzana A, Fibbi G. The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Curr Pharm Des 2011;17: 1924-43.
44. Gavins FNE. Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia-reperfusion injury? Trends Pharmacol Sci 2010;31 266-76.
45. Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signalling. Curr Pharm Des 2011;17: 1944-61.